Proteostasis Therapeutics’ Cystic Fibrosis Treatment Garners FDA Fast Track

Proteostasis Therapeutics has secured FDA fast track status for its PTI-428 for the treatment of cystic fibrosis.

The oral treatment selectively increases the amount of an immature form of the cystic fibrosis transmembrane conductance regulator protein, which provides additional substrate for other CFTR modulators to act upon.

A Phase 1 clinical trial will begin in the first quarter of 2016.